Be the first person to write a business review for Oncothyreon Inc.

Ondine Biopharma wants to offer an alternative to antibiotics for treating infections. The company is focused on the development and commercialization of its patented light-activated technology, called photodynamic disinfection, as a therapy for bacterial, fungal, and viral infections. Ondine Biopharma is developing a nasal system called MRSAid that incorporates hardware and photosensitizers to help treat often deadly hospital-acquired pathogens, such as staph infections. If commercialized, that product would give the company entry into the hospital infection control market.

Cancer is the only target of Onyvax. The development-stage biotech aims to come up with novel immunotherapies to treat advanced prostate and other forms of cancer. Onyvax's therapeutic cancer vaccines combine inactivated cell lines that create immune responses to tumor targets. The firm has several products in clinical trials, including lead candidate Onyvax-P, a cell vaccine that could treat hormone-resistant prostate cancer. While most of the company's candidates target specific types of cancer, its Onyvax-105 uses human monoclonal antibodies to attack the CD55 molecule, giving the therapy potential for treating many types of cancer.

Onyx Pharmaceuticals was founded in 1992 and is headquartered in Emeryville, California. Onyx Pharmaceuticals, Inc., a biopharmaceutical company, engages in developing therapies targeting the molecular mechanisms causing cancer in the United States and internationally. Its lead product includes Nexavar (sorafenib) tablets, a novel, oral multiple kinase inhibitor that targets proteins involved in tumor cell proliferation and angiogenesis. This product is being developed and marketed in collaboration with Bayer HealthCare Pharmaceuticals. The company is also conducting various ongoing trials on Nexavar for conditions, such as non-small cell lung cancer, melanoma, breast cancer, and other cancers. It also develops ONX 0801, an oncology compound in preclinical development stage, under a development and license agreement with BTG International Limited. In addition, Onyx Pharmaceuticals, through a development collaboration, option, and license agreement with S*BIO Pte Ltd, owns options to license the rights of ONX 0803 and ONX 0805. ONX 0803 is an orally available, potent, and selective inhibitor of JAK2; and ONX 0805 is a JAK2 inhibitor. Further, the company has a research and development collaboration agreement with Warner-Lambert Company to discover and commercialize small molecule drugs that restore the control of, or otherwise intervene in, the misregulated cell cycle in tumor cells.

Opexa Therapeutics was founded in 2003 and is based in The Woodlands, Texas. Opexa Therapeutics, Inc. operates as a biopharmaceutical company, developing autologous cellular therapies with the potential to treat major illnesses, including multiple sclerosis (MS) and diabetes. These therapies are based on Opexa's proprietary T-cell and adult stem cell technologies. The company's products include a T-cell therapeutic vaccine, Tovaxin, which is in clinical development for the treatment of MS. The adult stem cell technology is in the preclinical development stage. The company was formerly known as PharmaFrontiers Corp. and changed its name to Opexa Therapeutics, Inc. in June 2006.

Optimer Pharmaceuticals was founded in 1998 and is based in San Diego, California. Optimer Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing anti-infective products worldwide. The company develops products that treat gastrointestinal infections and related diseases. Its two late-stage anti-infective product candidates include Fidaxomicin, the lead product candidate and an antibiotic that is in second Phase III registration trial for the treatment of clostridium difficile-infections; and Prulifloxacin, a prodrug in the fluoroquinolone class of antibiotics, which completed second Phase III trials for the treatment of infectious diarrhea in travelers. It also develops OP-1068/CEM-101, an antibiotic for the treatment of upper and lower respiratory tract infections; OPT-88, a disease-modifying intra-articular, or within the cavity of a joint, therapy for osteoarthritis; OPT-822, a carbohydrate-based cancer immunotherapy for the treatment of metastatic breast cancer; and an OPopS drug discovery platform. The company has a collaborative research and development, and license agreement with Cempra Pharmaceuticals, Inc. to discover, develop, and commercialize drugs based on macrolide and ketolide compounds.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.